

Luciano Puzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4508001/publications.pdf>

Version: 2024-02-01

29
papers

670
citations

623734

14
h-index

552781

26
g-index

29
all docs

29
docs citations

29
times ranked

960
citing authors

#	ARTICLE	IF	CITATIONS
1	Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. <i>Analytical Biochemistry</i> , 2004, 335, 244-252.	2.4	89
2	S3 to S3' subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates. <i>Biochemical Journal</i> , 2003, 373, 981-986.	3.7	60
3	Comparative substrate specificity analysis of recombinant human cathepsin V and cathepsin L. <i>Archives of Biochemistry and Biophysics</i> , 2004, 430, 274-283.	3.0	60
4	Kininogenase activity of <i>Thalassophryne nattereri</i> fish venom. <i>Biochemical Pharmacology</i> , 2004, 68, 2151-2157.	4.4	55
5	Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6112-6115.	2.2	45
6	Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. <i>Biochemical Journal</i> , 2002, 368, 365-369.	3.7	39
7	3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1094-1098.	2.2	36
8	Isomannide-Based Peptidomimetics as Inhibitors for Human Tissue Kallikreins 5 and 7. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 128-132.	2.8	31
9	Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L. <i>Biological Chemistry</i> , 2005, 386, 1191-5.	2.5	30
10	Production of L-DOPA under heterogeneous asymmetric catalysis. <i>Catalysis Communications</i> , 2004, 5, 631-634.	3.3	28
11	Carboxydipeptidase activities of recombinant cysteine peptidases. <i>FEBS Journal</i> , 2004, 271, 1046-1053.	0.2	25
12	Isomannide derivatives as new class of inhibitors for human kallikrein 7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6072-6075.	2.2	22
13	A possible alternative mechanism of kinin generation in vivo by cathepsin L. <i>Biological Chemistry</i> , 2005, 386, 699-704.	2.5	17
14	Cathepsin V, but not cathepsins L, B and K, may release angiotensin-like fragments from plasminogen. <i>Biological Chemistry</i> , 2008, 389, 195-200.	2.5	16
15	Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 333-337.	2.1	14
16	The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1485-1489.	2.2	12
17	The tick-derived rBmTI-A protease inhibitor attenuates the histological and functional changes induced by cigarette smoke exposure. <i>Histology and Histopathology</i> , 2018, 33, 289-298.	0.7	12
18	Recombinant expression and characterization of a <i>Xylella fastidiosacysteine</i> protease differentially expressed in a nonpathogenic strain. <i>FEMS Microbiology Letters</i> , 2006, 261, 187-193.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 39-47.	5.5	10
20	Plasma prekallikrein/kallikrein processing by lysosomal cysteine proteases. <i>Biological Chemistry</i> , 2004, 385, 1087-91.	2.5	9
21	Defining the substrate specificity of mouse cathepsin P. <i>Archives of Biochemistry and Biophysics</i> , 2005, 435, 190-196.	3.0	9
22	Plasminogen hydrolysis by cathepsin S and identification of derived peptides as selective substrate for cathepsin V and cathepsin L inhibitor. <i>Biological Chemistry</i> , 2010, 391, 561-570.	2.5	7
23	Human Tissue Kallikreins-Related Peptidases Are Targets for the Treatment of Skin Desquamation Diseases. <i>Frontiers in Medicine</i> , 2021, 8, 777619.	2.6	7
24	Leviserpin: A Serine Peptidase Inhibitor (Serpine) from the Sugarcane Weevil <i>Sphenophorus levis</i> . <i>Protein Journal</i> , 2011, 30, 404-412.	1.6	6
25	Discovery of a new isomannide-based peptidomimetic synthesized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 314-318.	2.2	6
26	Vioserpin, a serine protease inhibitor from <i>Gloeobacter violaceus</i> possibly regulated by heparin. <i>Biochimie</i> , 2016, 127, 115-120.	2.6	5
27	Functional and structural characterization of an ecotin-like serine protease inhibitor from <i>Trypanosoma cruzi</i> . <i>International Journal of Biological Macromolecules</i> , 2020, 151, 459-466.	7.5	5
28	Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127626.	2.2	4
29	Functional and Evolutionary Characterization of a UDP-Xylose Synthase Gene from the Plant Pathogen <i>Xylella fastidiosa</i> , Involved in the Synthesis of Bacterial Lipopolysaccharide. <i>Biochemistry</i> , 2017, 56, 779-792.	2.5	0